Ceftolozane-Tazobactam for Febrile Neutropenia Treatment in Hematologic Malignancy Patients Colonized by Multi-Resistant Enterobacteriaceae: Preliminary Results from a Prospective Cohort Study

Keywords: Ceftolozane-Tazobactam; Febrile neutropenia; Hematologic malignancy; Carbapenem-sparing.

To the editor.

Patients with hematologic malignancies (H.M.) colonized by multi-resistant Enterobacteriaceae are at risk of bloodstream infection (B.S.I.) caused by the same pathogen. Some studies suggested that pre-existing colonization predicts 16-20% chance of developing a multi-drug resistant (M.D.R.) B.S.I. during the neutropenic phase. Moreover, several data clearly showed that a B.S.I. by multi-resistant Enterobacteriaceae in H.M. patients was associated with high early mortality in both transplant and non-transplant settings. The most used broad-spectrum approach for febrile neutropenia (F.N.) in Europe is Piperacillin-Tazobactam (PIP-TAZ), either associated or not with an aminoglycoside, depending on the severity of symptoms. However, this approach may be ineffective in colonized patients, and an up-front carbapenem-based approach or an early shift to a carbapenem treatment is often required. Consequently, a revision of the F.N. treatment strategy is warranted, which aims to move the current standard approaches forward, particularly in colonized patients. Ceftolozane-Tazobactam (CEF-TAZ) is a novel cephalosporin/beta-lactamase inhibitor combination that acts against M.D.R. gram-negative bacilli but not against carbapenem-resistant K. pneumoniae, approved for complicated urinary, abdominal and lung infections. To the best of our knowledge, there are no published studies on CEF-TAZ for the treatment of F.N. Based on our local epidemiology, which is characterized by a prevalence of extended-spectrum beta-lactamase producing (ESBL-P) Enterobacteriaceae and M.D.R. P. aeruginosa and a low incidence of carbapenem-resistant K. pneumoniae, we designed a single-institution prospective cohort study that aimed to implement a carbapenem-sparing strategy based on the hypothesis that a CEF-TAZ monotherapy was able to decrease the shift rate towards carbapenems in H.M. patients colonized by multi-resistant Enterobacteriaceae.

From Feb-2018, all consecutively hospitalized H.M. patients aged ≥ 18 years with an expectation of severe (< 200 neutrophils/mcL) and prolonged (≥ 7 days) neutropenia were enrolled in the study (mainly acute leukemias and stem cell transplants). All patients were screened at admission for M.D.R. microorganism colonization by rectal, nasal, pharyngeal, urethral/genital, and central venous catheter exit-site swabs and by urine and blood cultures, according to institutional guidelines. The algorithm proposed for F.N. treatment is summarized in Figure 1. Briefly, patients colonized by multi-resistant Enterobacteriaceae resistant to PIP-TAZ (M.I.C. > 4 mg/L) were treated with CEF-TAZ monotherapy (investigational cohort). In contrast, not colonized patients underwent our standard antibiotic approach based on PIP-TAZ/Amikacin, including patients colonized by multi-resistant Enterobacteriaceae susceptible to PIP-TAZ (M.I.C. ≤ 4 mg/L) (not colonized cohort). A third group consisted of a historical cohort of patients (admission to our Unit between Jan-2016 and Jan-2018), which were colonized by multi-resistant Enterobacteriaceae resistant to PIP-TAZ and were handled with PIP-TAZ/Amikacin at F.N. onset (historical control cohort). None of the enrolled patients was treated with fluoroquinolones as neutropenia prophylaxis, according to our current institutional policy. Patients colonized by carbapenem-resistant K. pneumoniae strains were excluded from this study. Criteria for initial treatment failure and shift towards a carbapenem-based treatment included persistent fever associated with one of the following signs occurring within 24-72 hours from the onset: 1) hemodynamic instability; 2) rapid respiratory
distress; 3) rapid clinical deterioration. B.S.I., sepsis, and septic shock were defined according to the Surviving Sepsis Campaign criteria. The M.A.S.S.C. score for F.N. risk was used to assess the severity of the patient's clinical presentation. The end-organ disease was defined as parenchymal dissemination due to the same microorganism causing B.S.I. In particular, pneumonia etiology was documented by performing a bronchoalveolar lavage fluid analysis, as previously described. The study was approved in the context of an institutional antimicrobial stewardship program (PT-DSA-01-2019-rev.0) and was conducted in accordance with the Helsinki declaration. All enrolled patients signed informed consent for data analysis for scientific purposes.

Bacterial identification was performed by using the MALDI-TOF MS system (Bruker Daltonics, Bremen, Germany). Antibiotic susceptibility was tested through the use of the VITEK®2 system (bioMérieux, Marcy-l'Etoile, France) and the broth microdilution test (Thermo Scientific, Massachusetts, U.S.A.) and the broth microdilution test (Thermo Scientific, Massachusetts, U.S.A.) was used for defining the M.I.C. criteria, according to the European on Antimicrobial Susceptibility Testing (E.U.C.A.S.T.) interpretative standards (www.eucast.org).

The primary end-point was the failure rate of CEF-TAZ (leading to a shift toward a carbapenem) as a first-line monotherapy approach for F.N. in patients colonized by multi-resistant Enterobacteriaceae. To verify the hypothesis that CEF-TAZ was able to decrease the global shift rate toward a carbapenem from 35% to 10% with a power of 80% at a significance level of 5% (two-sided test), it was necessary to enroll 43 patients in this investigational cohort. The study started in Feb-2018. Herein we report an interim-analysis carried out two years after the beginning of the study, focused on the comparison of shift rates toward carbapenems among the three cohorts of patients (investigational cohort, historical control cohort, not colonized cohort). Secondary end-points were the rates of documented B.S.I. and end-organ disease, the severity of symptoms associated with F.N., and 30-day attributable mortality. Statistical analyses were carried out using the S.P.S.S. software (S.P.S.S. version 21, S.P.S.S. Inc., Chicago, IL, U.S.A.). A P-value <0.05 was considered statistically significant.

Ten patients were enrolled in the investigational cohort, 104 patients in the not colonized cohort, and 18 patients formed the historical control. Out of 114 patients who were consecutively enrolled in the two prospective cohorts, 17 (15%) presented pre-existing colonization by multi-resistant Enterobacteriaceae, whereas the remaining 97 were not colonized. Among
the 17 colonized patients, 10 cases received CEF-TAZ at the F.N. onset, being colonized by multi-resistant Enterobacteriaceae with proven resistance to PIP-TAZ. In contrast, the remaining 7 patients received a standard antibiotic treatment based on PIP-TAZ/Amikacin, being colonized by multi-resistant Enterobacteriaceae susceptible to PIP-TAZ (Figure 1). In the 10 patients who received CEF-TAZ, all strains of colonizing multi-resistant Enterobacteriaceae proved to be resistant to PIP-TAZ and susceptible to CEF-TAZ. The 97 not colonized patients received PIP-TAZ/Amikacin. As for the primary end-point, the shift rate towards a carbapenem-based treatment in the group of patients treated with CEF-TAZ was 20%. As shown in Table 1, this rate was lower but not significantly lower than that observed in the not colonized cohort (25%) and in the historical control cohort (33%). As for the secondary end-points, at the F.N. onset, there were not any significant differences in terms of B.S.I., hemodynamic shock, end-organ disease, and 30-day attributable mortality (Table 1). In particular, 4 cases of B.S.I. were diagnosed in patients treated with CEF-TAZ, and in 2 out of these 4 cases, the isolated pathogen was the same one responsible for the pre-existing colonization (ESBL-P K. pneumoniae in both). Similar data were observed in our historical cohort, in which we reported 10 cases of B.S.I. with 4 of them characterized by the same pathogen responsible for the pre-existing colonization (ESBL-P E. Coli n=2, ESBL-P K. pneumoniae n=1, M.D.R. P. aeruginosa n=1). Finally, we did not notice any significant differences between the two groups in terms of antibiotic treatment duration (PIP-TAZO/Amikacin: 7 days, range: 1-14; CEF-TAZ: 6 days, range 3-11).

Table 1. Clinical parameters and outcome comparison among the three patient cohorts.

| Parameter                          | Patients colonized by MDR Enterobacteriaceae resistant to PIP-TAZ (N=10) | Patients colonized by MDR Enterobacteriaceae susceptible to PIP-TAZ or not colonized (N=104) | Patients colonized by MDR Enterobacteriaceae resistant to PIP-TAZ (historical cohort*, N=18) | p** |
|-----------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|-----|
| M/F                               | 3/7                                                                       | 53/51                                                                                      | 9/9                                                                        | NS  |
| Median age (range)                | 60 (44-68)                                                                | 59 (26-77)                                                                                 | 63 (19-77)                                                                                 | NS  |
| Diagnosis                         |                                                                           |                                                                                           |                                                                                            |     |
| Acute leukemia                    | 6 (60%)                                                                   | 65 (62%)                                                                                  | 9 (50%)                                                                                    | NS  |
| Lymphoma                          | 2 (20%)                                                                   | 25 (24%)                                                                                  | 7 (39%)                                                                                    |     |
| Myeloma                           | 2 (20%)                                                                   | 14 (14%)                                                                                  | 2 (11%)                                                                                    |     |
| Pre-existing colonization          |                                                                           |                                                                                            |                                                                                            |     |
| E. Coli ESBL-P                    | 3 (30%)                                                                   | 6^ (6%)                                                                                   | 10 (56%)                                                                                   | -   |
| K. pneumoniae ESBL-P              | 5 (50%)                                                                   | 1^ (1%)                                                                                   | 6 (33%)                                                                                    |     |
| P. aeruginosa MDR                 | 2 (20%)                                                                   | 0                                                                                        | 2 (11%)                                                                                    |     |
| None                              | 0                                                                         | 97 (93%)                                                                                  | 0                                                                                         |     |
| Median MASCC score at onset (range)| 16 (13-18)                                                               | 16 (4-21)                                                                                 | NA                                                                                         | NS  |
| Up-front treatment (at the FN onset)| CEF-TAZ                                                                  | PIP-TAZ/Amikacin                                                                            | PIP-TAZ/Amikacin                                                                            | -   |
| Shift to carbapenem-based treatment| 2 (20%)                                                                  | 26 (25%)                                                                                  | 6 (33%)                                                                                    | NS  |
| Documented BSI                    | 4 (40%)                                                                   | 66 (63%)                                                                                  | 10 (56%)                                                                                   | NS  |
| Hemodynamic shock                 | 2 (20%)                                                                   | 18 (17%)                                                                                  | 5 (28%)                                                                                    | NS  |
| End-organ disease                 | 0                                                                         | 10 (10%)                                                                                  | 3 (17%)                                                                                    | NS  |
| 30-days attributable mortality    | 0                                                                         | 3 (3%)                                                                                    | 0                                                                                         | NS  |

MDR: multi drug resistant; PIP-TAZ: Piperacillin-Tazobactam; ESBL-P: extended spectrum beta-lactamase producing; BSI: bloodstream infection; MASCC score: risk index for febrile neutropenia; NA: not available; NS: not significant; CEF-TAZ: Ceftolozane-Tazobatam.
*historical control patient cohort from January 2016 to January 2018; **Pearson’s Chi-Square non-parametric test; Mann-Whitney non-parametric test; ^all these microorganisms are not resistant to PIP-TAZ.
Several studies recently reported on the importance of adopting a carbapenem-sparing approach to reduce the pressure of carbapenem overuse, causing resistance.8 Even though we still have limited data on the use of CEF-TAZ in ESBL-P pathogens, this molecule appears to be a promising novel agent potentially able to modify the current antimicrobial approach.8-9 Two years after the beginning of the study, fewer patients than expected were enrolled in the investigational cohort. The use of CEF-TAZ at the F.N. onset in H.M. patients colonized by ESBL-P Enterobacteriaceae and M.D.R. P. aeruginosa resistant to PIP-TAZ determined a shift rate toward a carbapenem of 20%, lower but not statistically significantly different than that observed in all other patients treated with the standard antibiotic approach.

Moreover, we did not observe any significant differences in all the other parameters and outcomes analyzed among the three patient cohorts, including attributable mortality. Even if, at the first interim-analysis, our study failed to reach the primary endpoint, we believe that these results are relevant for at least three reasons. Firstly, there are only a few studies reporting data on the use of CEF-TAZ in H.M. patients10 and to our knowledge, there are still no published studies on CEF-TAZ for F.N. treatment. Secondly, a CEF-TAZ monotherapy was, however, able to decrease the carbapenem recourse rate in patients colonized by M.D.R. Enterobacteriaceae resistant to PIP-TAZ from 33% in the historical cohort to 20%, not enough to be statistically significant but enough to continue the study. Finally, a CEF-TAZ monotherapy was, however, able to equalize around 20-25% the carbapenem recourse rates between the colonized and not colonized patients, breaking down the additional risk given by the M.D.R. pathogens. In conclusion, given the limitation due to the low number of patients enrolled, CEF-TAZ monotherapy for F.N. treatment in H.M. patients colonized by ESBL-P Enterobacteriaceae and M.D.R. P. aeruginosa could be a promising carbapenem-sparing strategy. Further study is warranted to confirm these preliminary results.

Acknowledgments. We thank Tania Merlino (English mother tongue) for revising the manuscript.

Francesco Marchesi1*, Luigi Toma2, Enea Gino Di Domenico3, Ilaria Cavallo1, Antonio Spadea1, Grazia Prignano3, Fulvia Pimpinelli3, Elena Papa1, Irene Terrenato4, Fabrizio Ensoli3 and Andrea Mengarelli1.

1 Hematology and Stem Cell Transplant Unit, I.R.C.C.S. Regina Elena National Cancer Institute (Rome, Italy).
2 Department of Research, Advanced Diagnostics, and Technological Innovation, Translational Research Area, I.R.C.C.S. Regina Elena National Cancer Institute (Rome, Italy).
3 Microbiology and Virology, I.R.C.C.S. San Gallicano Dermatological Institute (Rome, Italy).
4 Biostatistics and Bioinformatic Unit, Scientific Direction, I.R.C.C.S. Regina Elena National Cancer Institute (Rome Italy).

Competing interests: The authors declare no conflict of Interest.

Correspondence to: Francesco Marchesi, MD. Hematology and Stem Cell Transplant Unit, I.R.C.C.S. Regina Elena National Cancer Institute, Via Elio Chianesi, 53 - 00144 Rome (Italy). Tel: +39 06 52665022. E-mail: francesco.marchesi@ifo.gov.it

References:

1. Cattaneo C, Di Blasi R, Skert C, Candoni A, Martino B, Di Renzo N, et al; S.E.I.F.E.M. Group. Bloodstream infections in haematological cancer patients colonized by multidrug-resistant bacteria. Ann Hematol. 2018;97:1717-1726. https://doi.org/10.1007/s00277-018-3341-6 PMid:29705860
2. Girmenia C, Bertaina A, Picciocchi A, Perruccio A, Kalarotiti A, Busca A, et al; Gruppo Italiano Trapianto di Midollo Osseo (G.I.T.M.O.) and Associazione Microbiologi Clinici Italiani (A.M.C.I.L.). Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. Clin Infect Dis. 2017;65:1884-1896. https://doi.org/10.1093/cid/cix690 PMid:29020286
3. Verlinden A, Mikula M, Kneelange NS, Averbuch D, Styczynski J; Infectious Diseases Working Party (I.D.W.P.) of the European Group for Blood and Marrow Transplantation Group (E.B.M.T.) Current antimicrobial practice in febrile neutropenia across Europe and Asia: the E.B.M.T. Infectious Disease Working Party survey. Bone Marrow Transplant. 2020 Feb 11. https://doi.org/10.1038/s41409-020-0811-y PMid:32047286 PMCID:PMC7391284
4. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock, 2016. Intensive Care Med. 2017;43:304-377. https://doi.org/10.1007/s00134-017-4683-6 PMid:28101605
5. Klasteksky J, Paansms M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18:3038-3051. https://doi.org/10.1200/JCO.2000.18.16.3038 PMid:10944139
6. Marchesi F, Cattaneo C, Criscuolo M, Delia M, Degenio M, Del Principe MI, et al.; Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) Group. A bronchoalveolar lavage-driven antimicrobial treatment improves survival in hematologic malignancy patients with detected lung infiltrates: a prospective multicenter study of the SEIFEM group. Am J Hematol. 2019;94:1104-1112. https://doi.org/10.1002/ajh.25585 PMid:31321791
7. Di Domenico EG, Rimoldi SG, Cavallo I, D’Agosto G, Trento E,
Cagnoni G, et al. Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis. B.M.C. Microbiol. 2019;19:228. 
https://doi.org/10.1186/s12866-019-1596-2
PMid:31638894 PMcid:PMC6802308

8. Karaiskos I, Giamarellou H. Carbapenem-sparing strategies for E.S.B.L. producers: when and how? Antibiotics. (Basel) 2020;9.
https://doi.org/10.3390/antibiotics9020061
PMid:32033322 PMcid:PMC7167803

9. Corcione S, Lupia T, Maraolo AE, Mornese Pinna S, Gentile I, et al. Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. Curr Opin Infect Dis. 2019;32:663-673.

10. Fernández-Cruz A, Alba N, Semiglia-Chong MA, Padilla B, Rodriguez-Macías G, Kwon M, et al. A case-control study of real-life experience of ceftolozane-tazabactam in patients with hematologic malignancy and Pseudomonas aeruginosa infection. Antimicrob Agents Chemother. 2019;63(2):e02340-18.
https://doi.org/10.1128/AAC.02340-18
PMid:30530598 PMcid:PMC6355614